OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Thoracic Oncology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Meeting Announcements	766
Better Together: Advancing Tobacco Use Treatment and Lung Cancer Screening	382
In This Issue/Research Watch/News in Brief	326
Board of Directors	321
Do We Really Understand the Relationship Between Expression of ACE2 and Coronavirus Disease 2019 Lung Pathophysiology?	308
Reply to Kus and Aktas	238
New Pulmonary Infiltrates Observed on Computed Tomography-Based Image Guidance for Radiotherapy Warrant Diagnostic Workup for Coronavirus Disease 2019	227
Letter to the Editor About Huber et al.	221
Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in NSCLC: A Brief Report	209
Anti–Vascular Endothelial Growth Factor/Programmed Cell Death Protein 1 Bispecific Antibodies: Using Nunchucks to Fight an Old Adversary	204
Prospective Cohort Study to Compare Long-Term Lung Cancer-Specific and All-Cause Survival of Clinical Early Stage (T1a–b; ≤20 mm) NSCLC Treated by Stereotactic Body Radiation Therapy and Surgery	191
Editorial Commentary: Baseline Radiomic Signature to Estimate Overall Survival in Patients With NSCLC	183
Board of Directors	178
“Tumor-free survival” Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC	169
A Response to the Letter to the Editor: “Prognostic Factors for Survival After Thymoma Distant Recurrence Resection”	168
Table of Contents	162
Editorial Comment: Validation Study for the N Descriptor of the Newly Proposed 9th Edition of the TNM Staging System Proposed by the International Association for the Study of Lung Cancer	158
Tobacco News Update—From the IASLC Tobacco Control Committee	154
Response to Commentary on “EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47”	153
Letter Regarding “Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib”	153
Board of Directors	137
Predicted Effect of Incidental Pulmonary Nodule Findings on NSCLC Mortality	126
DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy	125
Reducing pERKs to Break “RAS”istance to Sotorasib	124
In This Issue	114

Tobacco News Update—From the IASLC Tobacco Control Committee	114
Meeting Announcements	111
A Response to the Letter to the Editor: Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC	110
Table of Contents	108
Suggestions for Improving the Comprehensive Characterization of Lung Pleomorphic Carcinoma	106
Future Radiation Oncology: The Role of Personalization and Standardization in Stereotactic Body Radiotherapy	103
Board of Directors	102
Table of Contents	101
In This Issue	97
PP01.67 Evaluating immune-related adverse events (irAEs) in a real-world cohort with lung cancer receiving immunotherapy	96
Editorial Board	96
PP01.109 Concordance of Breast Density Between Low-Dose CT and Mammogram	94
PP01.112 Treatment Patterns and Outcomes in Second-Line Advanced NSCLC Treated After Prior Platinum Chemotherapy and Immunotherapy Combination Therapy: A Real-World Study	94
PP01.18 Real-world evaluation of racial and socioeconomic disparities in patients with NSCLC treated with immunotherapy	93
OA01.01 Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors	91
PP01.85 A Phase 2/3 Study of Fianlimab, Cemiplimab, plus Chemotherapy Versus Cemiplimab plus Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer	87
PP01.117 Real-World Effectiveness and Safety Profile of Lurbinectedin and Other Second-Line Treatments in Small Cell Lung Cancer	83
PPD01.02 Repotrectinib in Patients With ROS1 Fusion-Positive (ROS1+) NSCLC: Update From the Pivotal Phase 1/2 TRIDENT-1 Trial	83
PP01.172 It's Never Too Late To Quit	83
PP01.40 Treatment Patterns and Survival Outcomes of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Survival at a Safety-Net Hospital	80
PP01.101 Estimated Cost of Adverse Events and Surgery for Resectable Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Nivolumab Plus Platinum-Doublet Chemotherapy	79
PP01.65 Efficacy and Safety of Dose-Escalated Alectinib in Patients with Metastatic ALK-positive NSCLC and CNS Relapse on Standard Dose Alectinib	78
PPD01.06 Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-2 Study	77
PP01.23 Plasma cell-free RNA PD-L1 or Tissue PD-L1 Protein Expression and Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer	76
PP01.06 Role of number of pathologic N2 stations for future AJCC lung cancer staging versions	75
PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis	74
PP01.136 Understanding Experiences of Cancer-Related Fatigue in Patients with Lung Cancer After Their Cancer Treatment: A Qualitative Content Analysis	74
PP01.169 Promotion of Low-Dose Computed Tomography Screening and Blood Biomarkers in Minority Communities for Early Detection of Lung Cancer in Northern Illinois	72
PP01.74 LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study	72
PP01.90 Real-world Demographics, Clinical Characteristics, Treatment Patterns and Clinical Outcomes for US Patients with Limited-Stage SCLC (LS-SCLC)	71
PP01.26 Proprietary vs Open-Source Radiomic Platform for Lung Cancer Diagnosis	71
PP01.20 Hospitalization patterns for immune-related adverse events in patients with NSCLC treated with immunotherapy vs chemo-immunotherapy	70
PP01.108 Trial in Progress: Shared Decision-Making Encounter Tool for Adjuvant Treatment of Lung Cancer: Randomized Control Trial	68
PP01.135 Outcomes and Treatment Patterns for Recurrence following Concurrent Chemoradiation and Consolidation Immunotherapy in Unresectable Stage III NSCLC: A Multi-Center Study	67
EP08.02-061 Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?	66
EP08.02-076 Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab	66
EP08.02-077 Two Phase III Trials of Aumolertinib Plus Chemotherapy for NSCLC with EGFR and Concomitant non-EGFR Driver Genes /Tumor Suppressor Genes	65
P54.05 Stereotactic Radiotherapy for Brain Metastases in Patients With Lung Cancer: Cyberknife Experience	65
EP08.02-080 EGFR Testing Practices, Treatment Choice and Clinical Outcomes in Advanced NSCLC in a Real-World Setting	64
P53.08 Concomitant Fibrates and Immunotherapy in Non-Small Cell Lung Cancer Patients in the Veterans Health Administration	63
EP08.02-088 Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients	63
P54.04 Detecting Elevated Risk of Diminished Quality of Life Among Lung Cancer Patients by Using Wearable Devices	62
P56.01 Semiquantitative Assessment of Tumor Spread Through Air Spaces in a Historic Cohort of Lung Adenocarcinomas Following Open Surgical Resection	62
EP08.02-097 Prevalence, Clinical Characteristics and Survival of Patients With Brain Metastases and KRAS Mutation Lung Cancer in Argentina	61
EP08.02-050 A Retrospective Study of Aumolertinib in Combination with Bevacizumab for EGFR-mutated NSCLC with the Presence of Leptomeningeal Metastasis	60
EP08.02-043 The Current State of Biomarker Testing in Lung Cancer as Seen by Health Care Providers	60
P48.03 Spectrum of Resistance Mechanisms to First, Second and Third Generation Tyrosine Kinase Inhibitors in EGFR Mutant NSCLC Patients	58
P48.15 EGFR Mutated Non-Small Cell Lung Cancer Treatment Pathway – What Is the Best Way?	58
P51.01 Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)	57
P48.08 The Efficacy and Clinical Survival Outcome of Different First-Line Treatments in EGFR Mutant Non-Small Cell Lung Cancer With Brain Metastases	57

EP08.02-063 SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC	56
EP08.02-130 Tegavivint Exhibits Antitumor Activity and Modulates Macrophage Phenotype in the Non-small Cell Lung Cancer Tumor Microenvironment	56
P50.06 First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate	56
EP08.02-167 Diverse Effects of Radiotherapy for Osimertinib Acquired Resistance Non-small Cell Lung Cancer: Gene Matters	55
EP08.02-128 Long Term Efficacy of SNK01 Plus Pembrolizumab for NSCLC: Expanded Observation from a Phase I/II A Randomized Controlled Trial	54
P59.01 Clinical Characteristics of Patients With MET Amplification-Positive NSCLC After EGFR-TKI Therapy	54
P59.18 Evaluation of ROS1 Expression in a Large Cohort of Early Stage Lung Cancer	54
EP08.04-003 A Simple Clinical Prediction Score to Determine Response to First Line Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients	52
EP10.01-016 Cachexia’s Impact on Immunotherapy Dose Reduction, Treatment Discontinuation, and Survival: a Systematic Review	50
P60.13 MYLUNG Consortium: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network. Pragmatic Prospective RWR Study	50
EP10.01-002 The Effect of Group Rehabilitation Training in the Ward on the Psychological Status and Quality of Life of Lung Cancer Patients	50
P47.06 TROPION-Lung04: Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab and Platinum-Based Chemotherapy in Advanced NSCLC	49
69P VMAT based SBRT in early stage NSCLC: Outcomes and toxicities	49
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)	49
P61.05 Time to Loosen Up: Liberalizing Lung Cancer Screening Guidelines Might Save More Lives	49
PP01.30 Integration of molecular cancer classification and NGS to identify patients with cancer of unknown primary (CUP) and other unclear diagnoses eligible for KRAS inhibitors	49
Beyond Personalized to “Tumoralized” Therapy	47
Table of Contents	47
Outcomes by ALK Status (Immunohistochemistry or Fluorescence In Situ Hybridization) in ALEX	47
Hippocampal Avoidance Prophylactic Cranial Irradiation for SCLC	47
Editorial Board	46
Real-World Evidence of the Association Between Rheumatoid Arthritis and Lung Cancer	46
EGFR Tyrosine Kinase Inhibitor Sequencing Revisited: From the Revival of Old Tools to the Integration of New Agents	46
Lung Cancer in Colombia	45
Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC	45
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC	45
Pitfalls in Molecular Testing and the Added Value of the Cancer Research Biomedical Community	44
Board of Directors	44
Response to Letter to the Editor From Binghao Zhao et al	43
P14.01 Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC	43
The Anti–Programmed Cell Death Protein-1/ Programmed Death-Ligand 1 Me-Too Drugs Tsunami: Hard To Be Millennials Among Baby Boomers	42
P49.01 Drug Holiday Based on Minimal Residual Disease Status After Local Therapy Following EGFR-TKI Treatment for Patients With Advanced NSCLC	42
OA01.02 Impact of COVID-19 Outbreak on Lung Cancer Diagnosis and Continuum of Care: Data From an Italian Multicenter Study	42
Response to the Letter to the Editor Titled “First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA”	41
Potential Impact of Criteria Modifications on Race and Sex Disparities in Eligibility for Lung Cancer Screening	41
Stage Shift Improves Lung Cancer Survival: Real-World Evidence	41
P40.13 Lung Cancer 5-Year Survival in Croatia - Our Experience	40
Table of Contents	40
P34.05 Three Birds, One Stone: IVIG Use in Hypogammaglobulinemia, Checkpoint Inhibitor Pneumonitis, and Persistent COVID-19	40
P40.14 Efficacy and Safety of Endostar Combined With Camrelizumab and Chemotherapy in Treatment of Advanced NSCLC: A Multi-Center Retrospective Study	40
P39.01 Long-Term Outcomes and Characteristics of Unresectable Locally Advanced Thymic Malignancies	39
P36.03 Rapidly Progressed Anaplastic Carcinoma in the Anterior Mediastinum Successfully Treated With Gene-Targeted Therapy	39
P39.05 Outcomes of Videothoracoscopic Thymectomy for Treatment Large-Sized Thymomas	38
P37.01 The Results of Multimodal Treatment With Extrapleural Pneumonectomy for Female Epithelioid Malignant Pleural Mesothelioma	37
P34.04 Chemo-Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) – Real World Data from a Tertiary Oncology Centre	37
P37.03 The Epidemic of Malignant Mesothelioma in China: A Prediction of Incidence During 2016-2030	36
EP08.02-027 T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC	36
P42.04 Prognosis Factors in Advanced Lung Cancer Patients Treated With Checkpoint Inhibitor-Based Immunotherapy	36
P39.04 Thymic Epithelial Tumors: The Importance of Invasive Investigation to Adequate Diagnosis	36
P45.14 Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China	36
P41.01 Abscopal Response Induced by Thermal Ablation in Advanced NSCLC Patients Failed From Immunotherapy: Preliminary Result From a Phase 2 Trial	36
EP08.01-104 Baseline Tumor Size and Survival Outcomes among Patients with Advanced NSCLC treated with First-Line Immunotherapy	36
EP08.02-006 Data from Real World to Evaluate the Efficacy of Almonertinib in EGFR-mutant NSCLC Patients	36
EP08.01-110 Trial in Progress: A Phase 2 Multicenter Study (IOV-LUN-202) of Autologous Tumor-infiltrating Lymphocyte (TIL) Cell Therapy (LN-145) in mNSCLC	35
P38.02 The Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) In Lung Metastasectomy for Colorectal Cancer: A Meta-Analysis	35
P45.03 Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC as Identified by Liquid (LBx) or Tissue (TBx) biopsy	35
EP08.02-013 Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1Fusion-Positive NSCLC	35
P45.11 Co-occurring CDKN2A/B Alteration Is Associated With Worse Survival Outcomes in Advanced ALK-Positive Non-Small Cell Lung Cancer	35
P40.11 Trimodality Therapy Protocol in 144 Superior Sulcus Patients: Good Results Even for Extended Resections and Indications	35
P57.12 Clinical and Molecular Features of Chinese Lung Cancer Patients With Germline Mismatch Repair Gene Mutations	34
P59.06 Prognostic Nutritional Index in Real-World Patients Receiving Systemic Therapy for Driver Mutation-Positive Metastatic NSCLC	34
P45.05 Sequencing of PD-1 Inhibitors and TKIs in Metastatic NSCLC with MET Exon 14 Skipping Mutation May Influence Survival	34
P59.04 Molecular Characterization of Unactionable EGFR Mutation in Non-Small Cell Lung Cancer	34
EP08.02-091 Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA	33
EP08.02-100 Combination of Bevacizumab and Continuation of EGFR-TKIs in NSCLC Patients beyond Gradual Progression	33
P56.06 Clinical Significance and Potential Function of S100A10 in Lung Adenocarcinoma	33
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC	33
EP08.02-108 Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study	33
EP08.02-119 RNA Sequencing to Characterize Pathways in EGFR-mutated Non-Small Cell Lung Cancer	32
EP08.01-024 Multicenter Real Life Clinical Outcomes of PDL-1 Tested Patients with Non Small Cell Lung Cancer (NSCLC) in Turkey	32
EP08.01-053 PD-1 Inhibitors Plus Chemotherapy in Patients with Brain Metastasis and EGFR/ALK-positive Non-small Cell Lung Cancer after EGFR/ALK-TKIs	32
EP08.01-021 Phase 2 Study Evaluating Inupadenant in Combination with Chemotherapy in Adults with NSCLC who Progressed on Immunotherapy	32
EP08.01-036 Low-dose EGFR-TKIs Directly Induce Maturation and Functional Activity of Human Dendritic Cells in an EGFR-independent manner	32
EP08.01-056 Pemetrexed-Based Chemotherapy Plus ICIs or Bevacizumab as First-Line Strategy for Patients with Lung Adenocarcinoma in Real-World Setting	32
EP08.02-107 Molecular Biomarker Testing and Initiation of Targeted Therapy in Minority Patients with Stage IV Non-small Cell Lung Cancer	32
EP08.01-022 Treatment Outcomes of Second-Line Immune Modulators in Steroid Refractory/Resistant Immune Related Adverse Events	32
EP08.01-051 Clinical Characterization and Outcomes of Non Small Cell Lung Cancer with HER2 Alterations in the Era of Immunotherapy	32
EP08.01-062 Body Mass Index, Immune Related Adverse Events, and Survival in Patients with Metastatic Non-small Cell Lung Cancer Treated with Immunotherapy	31
EP08.01-076 KEYNOTE B36: A Pilot Study of First-line Tumor Treating Fields (150 kHz) Plus Pembrolizumab for Advanced or Metastatic Non-small Cell Lung Cancer	31
EP08.01-055 Utilization of Tumor Mutational Profiling to Identify the Immunotherapy Response in Non-small Cell Lung Cancer	31

EP08.01-086 Pooled Mutant KRAS-Targeted Peptide Vaccine with Nivolumab and Ipilimumab in Advanced KRAS Mutated Non-Small Cell Lung Cancer	31
EP08.01-063 Chemoimmunotherapy versus Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer with a PD-L1 Score of 50-100%	31
EP08.01-079 Long Term Use of Immune Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer (NSCLC) and Abnormal Marrow Pathology: A Case Series	31
P26.01 Detecting Oligo-Metastatic/Progressive Disease in Advanced EGFR-Mutant NSCLC: PET/CT and Conventional Imaging Methods	30
EP08.01-093 ICI in Combination With Chemotherapy or Anti-angiogenic Agents as Second-Line Orbeyondtreatment for Advanced Non-small Cell Lung Cancer	30
EP07.01-002 Surgery in Stage I-III Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and End Results (SEER)- Medicare Analysis 1995-2015	30
EP08.01-087 First-Line Pembrolizumab-Combination Therapy for Advanced Squamous NSCLC: Real-World Outcomes at US Oncology Practices	30
201P RNA-based plus DNA-based analysis of METexon 14 skipping in a non-small cell lung cancer increases diagnostic performance	30
213P Development of an explainable clinical decision support tool for advanced lung cancer patients	29
EP07.01-007 Is Extended Resection for Tracheo Bronchial Adenoid Cystic Carcinoma Warranted ?	29
209P Clinicopathological features and survival outcome of keratinizing versus non-keratinizing squamous cell lung cancer	29
EP07.01-011 Integrating PD-L1 Expression to the CALGB Prognostic Scoring System in Malignant Pleural Mesothelioma	28
218P Implications of the eighth edition of TNM staging system for thymoma, a single-center retrospective study	28
211P The impact of the COVID-19 pandemic on lung cancer stage shift and the delivery of surgical lung cancer care in the United States	28
EP07.01-024 Preclinical Investigation of Immune Checkpoint Blockade and Anti-Angiogenic Therapy in Malignant Pleural Mesothelioma	27
P27.07 Pancoast Tumour Presenting as Lower Limb Weakness; Would You Recognise It?	27
P29.01 Deformable vs. Rigid Registration in Evaluating Composite Doses to Central Organs at Risk in Thoracic Reirradiation	27
EP07.01-022 Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)	27
221P Comparison of efficacy and safety of carboplatin combined with nab-paclitaxel or paclitaxel as first-line therapy for advanced thymic epithelial tumors	27
EP07.02-002 Investigating the Role of MicroRNAs in Cell Growth and Cisplatin-Sensitivity of Malignant Pleural Mesothelioma	27
EP07.01-016 Role of Neoadjuvant Chemotherapy in Thymic Tumors	27
EP07.02-006 Tumor Immune Microenvironment Related Makers are Overexpressed and Served as Favourable Prognostic Factors in Resectable ESCC	26
EP07.03-001 Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma	26
EP07.01-018 Phase III Randomized Trial on Surgery, Chemo and Pleural Radiation (IMPRINT) for Resectable Pleural Mesothelioma (NRG LU-006)	26
EP07.02-003 Characterization of the Extracellular Vesicle-Derived Transcriptome in Malignant Pleural Mesothelioma	26
EP07.03-005 MesoGraph: Graph Neural Networks for Weakly Supervised Cellular Profiling in the Subtyping of Malignant Mesothelioma Images	26
EP07.01-019 Multiinstitutional Patterns of Use and Compliance with Tumor Treating Fields for Patients with Unresectable Malignant Pleural Mesothelioma	25
EP08.01-012 First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience	25
EP08.01-002 Real-World Survival Outcomes of Patients with High PD-L1 Advanced NSCLC Who Received Chemo-Immunotherapy vs Immunotherapy	25
P33.01 Air Leak Due COVID-19 in a Lung Cancer Patient	25
P30.02 Salvage Surgery in Patients With Locally Advanced Non-Small Cell Lung Cancer – Outcomes and Longtime Results	25
P29.07 A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC	25
P05.02 Does Non-Small Cell Lung Cancer Histologic Type Influence Outcomes with Single-Fraction Stereotactic Body Radiotherapy?	24
90P Cell-free DNA as a predictive and prognostic marker in adjuvant-treated non-small cell lung cancer	24
P06.07 Learning Curve in Robotic-Assisted Thoracoscopic Pulmonary Resection: Experience of a Brazilian Surgeon	24
73P Qualitative research to evaluate perceptions around biomarker testing and patient-reported outcomes (PROs) for use in studies of non-small cell lung cancer (NSCLC)	24
P07.03 Lung Cancer Under 50 Years Old – What Reality Taught Us	24
P05.05 Impact of Lung Stereotactic Body Radiotherapy on Pulmonary Function Test – Experience from Tertiary Cancer Centre in India	24
P08.05 Impact of Personal Characteristics on the Effectiveness of Immunotherapy Treatment in Late-Stage NSCLC: A Systematic Review	24
P06.08 Treatment Outcome of Second Primary Lung Cancer	24
105P Development and assessment of artificial intelligence detection of lung nodules on chest roentgenograms	23
EP04.01-007 Impact of Precision Medicine Methods on First-Line Therapies in Metastatic Non-Small Cell Lung Cancer	23
110P Volumetric tumor volume doubling time in lung cancer: A systematic review and meta-analysis	23
106P AI negative predictive performance exceeds that of radiologists in volumetric-based risk stratification of lung nodules detected at baseline in a lung cancer screening population	23
P09.01 Waiting Time and Lung Cancer Outcomes: Association and Methodological Results From a Systematic Review of Systematic and Scoping Reviews	23
P09.05 Variation of Treatment Recommendations for Stage III Non-Small-Cell Lung Cancer by Stage and Actionable Mutations	23
P09.03 Validation of a Real-World Mortality Endpoint for Advanced Non-Small Cell Lung Cancer Patients in China	23
EP04.01-019 Into the Wild: Assessing Acute Care for Lung Cancer Patients, A Cohort Study to Improve Cancer Care at Emergency Department	23
EP04.01-015 Lung Cancer after Solid Organ Transplantation - A Claims Data Analysis	22
EP04.01-012 Sex and Age-Related Guideline-Adherence Disparities in Non-Small-Cell Lung Cancer Treatment Patterns: Real-World Data	22
P05.04 Retrospective Study on the Correlation of Central Tumour and Central Structures and the Effect on Survival for Patients Receiving Lung SABR	22
P09.07 Integration of Smoking Cessation Services in Mobile Mammography and Mobile COVID Screening to Reach Rural Populations	22
101P Evidence base for exercise prehabilitation suggests favourable outcomes for patients undergoing surgery for non-small cell lung cancer despite being of low therapeutic quality: A systematic revie	22
69P The effect of inflammatory-nutritional prognostic scoring system (INPS) on treatment response and prognosis in patients with metastatic NSCLC as second-line treatment with nivolumab	22
EP04.01-011 Diagnostic Approach and Treatment of Lung Cancer Patients in Portugal: Portuguese Lung Cancer Study Group Survey	22
EP04.01-001 Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience	22
EP04.01-020 Impact of Next-Generation Sequencing on Treatment Choice Among Patients with Metastatic NSCLC from the CHUM University Center	22
EP05.01-023 Feasibility of Functional Lung Avoidance using Ga-68 4D Ventilation Perfusion PET/CT: The HI-FIVE Trial	21
EP05.01-028 Thoracic Radiotherapy of Baseline Severe Pulmonary Dysfunction NSCLC Patients and Predictive Analysis for Acute Radiation Pneumonitis	21
EP05.01-019 4D CT Ventilation Image-Guided Lung Functional Avoidance Radiotherapy: A Single-Arm Prospective Pilot Clinical Trial	21
EP05.01-025 Planned Interim Analysis of a Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer	21
EP05.01-030 CRISP: First Real-World Evidence of NSCLC Stage I, II and III in Germany - AIO-TRK-0315	21
153P Molecular epidemiology of EGFR mutations in NSCLC: A single-center experience from India	21
157P Building a global evidence map of low-dose CT lung cancer screening implementation: Approach and data analysis opportunities	21
P16.03 SWItch Maintenance PEmbrolizumab in patients with Non Small Cell Lung Cancer (SWIPE): Final Analysis	21
EP05.03-010 Extended Resection of Non-small Cell Lung Cancer with Superior Vena Cava Involvement: A Systematic Review and Meta-analysis	20
193P Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC	20
P23.02 Digital Multiplexed circRNA Analysis From Plasma-Derived Extracellular Vesicles of Lung Cancer Patients	20
113P Clinical overstaging in pathologic stage I non-small cell lung cancer: Prognostic implications	20
EP06.01-004 Lung Cancer Resection During the Covid-19 Pandemic: A Single Centre Study	20
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC	20
199P Suppression of mutant Kirsten-RAS (KRAS G12C) non-small cell lung cancer (NSCLC) resistance to KRAS G12C inhibitors by dual inhibition of hepatocyte growth factor receptor (MET) and V-ATPase	20
192P ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations	20
115P Salvage surgery in patients with locally advanced or metastatic non-small cell lung cancer	19
117P Survival outcomes of surgery-based treatment or definitive chemoradiation with immunotherapy consolidation in stage IIIA NSCLC in the immune therapy era: An NCDB analysis	19
116P Survival outcome of chemotherapy in stage IIIA and IIIB non-small cell lung cancer	19
P10.09 Efficacy and Toxicity of EGFR-TKI in Frail NSCLC with EGFR Mutation: A Retrospective Analysis in a Single Institution	19
P10.11 Real-World Experience With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer at Frankfurt University Hospital	18
125P Real-world treatment patterns in stage III NSCLC patients: Interim results of a prospective, multicenter, non-interventional study (MOOREA)	18
132TiP Boosting immune response with copanlisib in locally advanced unresectable non-small cell lung cancer starting durvalumab consolidation: A phase Ib study	18
135P Macroscopic complete resection versus non-surgical management for malignant pleural mesothelioma	18
123P Second progression-free survival (PFS2) after first progression in patients receiving PACIFIC regimen: An exploratory analysis of the Blue Sky observational study	18
EP04.02-004 The Patient Impact of Liquid Biopsy - Health-Related Quality of Life in Patients Undergoing Liquid Biopsy for Advanced Non-Small Cell Lung Cancer	18
EP04.02-006 Burn-Out Syndrome: Neglected Syndrome Among Health Care Professionals Managing Lung Cancer Patients	18
139P Gemcitabine as maintenance treatment of malignant pleural mesothelioma (GEMO): Randomized phase II study	18
EP04.01-025 Implementation of Electronic Patient Reported Outcomes in Routine Cancer Care	18
EP04.02-001 Sex as a Potential Independent Prognostic Factor in Non-Small Cell Lung Cancer Survival	18
P12.01 A Novel 89Zr-α-PD-1 Immuno-PET-CT May Improve Pseudoprogression Detection in a Lung Cancer Murine Model Receiving Immunotherapy	18
EP05.01-003 First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area	18
EP05.01-002 Real World Treatment Patterns and Outcomes among Unresectable Stage III Non-Small Cell Lung Cancer Patients Initiating Chemoradiotherapy	18
59P Patterns of recurrence and survival after complete resection of pathological stage N2 small cell lung cancer	17
EP14.05-005 Survival of Small Cell Lung Cancer in Relation to Chemotherapy Dose Intensity	17
64MO Early experience of bronchoscopic transbronchial microwave ablation of lung nodules in the hybrid operating room	17
EP08.02-047 The Impact of CGP on the Decision-making Process in ALK+ aNSCLC After Failure of 2nd/3rd-Generation ALK TKIs	17
P66.08 Differential Expression of INSM1 Between Pure SCLC and LCNEC After Surgical Resection and Its Clinicopathological Significance	17